Perspective Therapeutics (NYSE:CATX) Shares Gap Up - Still a Buy?

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $11.69, but opened at $12.28. Perspective Therapeutics shares last traded at $11.93, with a volume of 14,121 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Oppenheimer reiterated an "outperform" rating and set a $22.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 11th. Bank of America assumed coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a "buy" rating and a $24.00 target price on the stock. Truist Financial assumed coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price target for the company. UBS Group assumed coverage on shares of Perspective Therapeutics in a research report on Thursday. They set a "buy" rating and a $20.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $20.63.

Perspective Therapeutics Stock Up 1.7 %

The firm has a 50 day moving average of $13.84.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. Analysts anticipate that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bleakley Financial Group LLC purchased a new stake in Perspective Therapeutics during the first quarter worth $40,000. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $57,000. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics during the 2nd quarter valued at about $117,000. Point72 DIFC Ltd acquired a new position in Perspective Therapeutics during the second quarter worth about $118,000. Finally, RIA Advisory Group LLC grew its position in shares of Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company's stock valued at $127,000 after purchasing an additional 99,293 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.